Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones
13 mars 2018 07h30 HE
|
Epizyme, Inc.
First Tazemetostat NDA Submission for Epithelioid Sarcoma Targeted for Fourth Quarter of 2018; Second Tazemetostat NDA Submission for Follicular Lymphoma Targeted for 2019 Multiple Phase 2 Study Data...
Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors
12 mars 2018 16h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the appointment of...
Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference
12 mars 2018 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation at the Cowen 38th Annual Health Care Conference
27 févr. 2018 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme to Participate in Leerink Partners 7th Annual Global Healthcare Conference
07 févr. 2018 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of Hematology Annual Meeting
11 déc. 2017 07h31 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel...
Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting
10 déc. 2017 10h00 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two...
Epizyme to Present at the Jefferies 2017 London Healthcare Conference
09 nov. 2017 06h30 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will...
Epizyme Reports Third Quarter 2017 Operating Results and Company Updates
01 nov. 2017 16h02 HE
|
Epizyme, Inc.
Company Scheduled for First FDA Interaction for Tazemetostat in NHL in 4Q17 Chief Medical Officer, Dr. Peter Ho, to Transition from Epizyme at the End of 2017; Will Continue to Support Upcoming...
Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children with Relapsed or Refractory INI1-Negative Solid Tumors at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
27 oct. 2017 09h15 HE
|
Epizyme, Inc.
CAMBRIDGE, Mass., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced encouraging data from...